Politicization of the new COVID-19 anti-viral drug has already begun and some are already banking on it to bring the economy back from the brink of collapse.
The blame game is now beginning as well, with who is to blame for this drug’s unavailability up until this point. Because apparently, first world countries like the United States need more drugs to advertise on television every night while people mentally ingest their daily dose of propaganda from “top shelf sources” like CNN and NBC.
Many are perplexed that the markets haven’t responded to yet another pharmaceutical creation even though the Phase III trial showing molnupiravir reduced the risk of hospitalization or death by approximately 50% for patients with mild or moderate COVID-19. But more importantly to those economists and talking heads is the economic impact this drug will have. Molnupiravir has boosted the stock of Merck by as much as 11%, while the broader market reaction hasn’t been great.
It is all about money when creating and marketing a product. And while there’s nothing wrong with that, it’s capitalism in action, hinging ones hopes on one drug creation may turn out to be a letdown.
It often looks like most people are more concerned about the “market’s reaction” to a new drug than they are to benefits or side effects to the general population. That’s unlikely to change too, but perhaps the populace is already inundated and saturated with enough drugs to keep them busy and doped up for the time being.
93% Of Investors Generate Annual Returns, Which Barely Beat Inflation.
Wealth Education and Investment Principles Are Hidden From Public Database On Purpose!
Build The Knowledge Base To Set Yourself Up For A Wealthy Retirement and Leverage The Relationships We Are Forming With Proven Small-Cap Management Teams To Hit Grand-Slams!
However, there is a push to tie this drug to the economy as a whole.
“In our view, this development has great potential to fully reopen the global economy. At $700 per course, it is not cheap, but is far cheaper than the cost of hospital treatment. Likewise, because it specifically targets those patients who are most at risk, the drug is likely to lessen the political cost of reopening, leaving the level of infections unchanged but massively reducing hospitalizations and deaths,” said James Terrar and Ed Cole in a note.
It all comes across as carefully crafted marketing points, to be brutally honest. Maybe this pill is a good thing. Maybe it isn’t. Big pharmaceutical companies have not been exactly forthcoming with information on their products, nor are they liable for damages up to and including death from certain treatments that are in the process of being mandated and forced on the public at large.
From all of this, we can gather that the creation of new drugs is not really about health, as much as it is about profits. Because of that, we, the consumers, need to do our due diligence on these drugs and make sure we are not coerced by anyone profiting off of our consumption of them.
Governments Have Amassed ungodly Debt Piles and Have Promised Retirees Unreasonable Amounts of Entitlements, Not In Line with Income Tax Collections. The House of Cards Is Set To Be Worse than 2008! Rising Interest Rates Can Topple The Fiat Monetary Structure, Leaving Investors with Less Than Half of Their Equity Intact!
Protect Yourself Now, By Building A Fully-Hedged Financial Fortress!
We are not brokers, investment or financial advisers, and you should not rely on the information herein as investment advice. We are a marketing company. If you are seeking personal investment advice, please contact a qualified and registered broker, investment adviser or financial adviser. You should not make any investment decisions based on our communications. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT recommendations. The securities issued by the companies we profile should be considered high risk and, if you do invest, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEC filings, press releases, and risk disclosures. Information contained in this profile was provided by the company, extracted from SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.
Please review our entire disclaimer at FutureMoneyTrends.com/disclaimer.